These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 24605976)

  • 21. [Continuing education. Clinical trials].
    Sökeland J
    Urologe A; 1990 Nov; 29(6):W41-2. PubMed ID: 2291253
    [No Abstract]   [Full Text] [Related]  

  • 22. Nonparametric analysis of covariance for hypothesis testing with logrank and Wilcoxon scores and survival-rate estimation in a randomized clinical trial.
    Tangen CM; Koch GG
    J Biopharm Stat; 1999 May; 9(2):307-38. PubMed ID: 10379696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statistical comparison of random allocation methods in cancer clinical trials.
    Hagino A; Hamada C; Yoshimura I; Ohashi Y; Sakamoto J; Nakazato H
    Control Clin Trials; 2004 Dec; 25(6):572-84. PubMed ID: 15588744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Revisiting the level of evidence in randomized controlled clinical trials: A simulation approach.
    Bajard A; Chabaud S; Pérol D; Boissel JP; Nony P
    Contemp Clin Trials; 2009 Sep; 30(5):400-10. PubMed ID: 19576298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Permutation test following covariate-adaptive randomization in randomized controlled trials.
    Hasegawa T; Tango T
    J Biopharm Stat; 2009; 19(1):106-19. PubMed ID: 19127470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Critical analysis of a parallel group randomized trial].
    Giraudeau B
    Rev Pneumol Clin; 2002 Nov; 58(5 Pt 1):261-7. PubMed ID: 12486375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Up-front versus sequential randomizations for inference on adaptive treatment strategies.
    Ko JH; Wahed AS
    Stat Med; 2012 Apr; 31(9):812-30. PubMed ID: 22362642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methods for mid-course corrections in clinical trials with survival outcomes.
    Cook TD
    Stat Med; 2003 Nov; 22(22):3431-47. PubMed ID: 14601011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptive covariate adjustment in clinical trials.
    Wang SJ; Hung HM
    J Biopharm Stat; 2005; 15(4):605-11. PubMed ID: 16022166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The type I error and power of non-parametric logrank and Wilcoxon tests with adjustment for covariates--a simulation study.
    Jiang H; Symanowski J; Paul S; Qu Y; Zagar A; Hong S
    Stat Med; 2008 Dec; 27(28):5850-60. PubMed ID: 18759373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adaptive trial design: a general methodology for censored time to event data.
    Jahn-Eimermacher A; Ingel K
    Contemp Clin Trials; 2009 Mar; 30(2):171-7. PubMed ID: 19130902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized controlled trials with time-to-event outcomes: how much does prespecified covariate adjustment increase power?
    Hernández AV; Eijkemans MJ; Steyerberg EW
    Ann Epidemiol; 2006 Jan; 16(1):41-8. PubMed ID: 16275011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data.
    Kombrink K; Munk A; Friede T
    Stat Med; 2013 Aug; 32(18):3055-66. PubMed ID: 23508697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blinded sample size reestimation in non-inferiority trials with binary endpoints.
    Friede T; Mitchell C; Müller-Velten G
    Biom J; 2007 Dec; 49(6):903-16. PubMed ID: 17726715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design considerations in crossover trials with a single interim analysis and serial patient entry.
    Cook RJ; Willan AR
    Biometrics; 1996 Jun; 52(2):732-9. PubMed ID: 8672709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 4: One method.
    Ball G
    Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S11-7. PubMed ID: 21651993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design of adaptive two-stage double-arm clinical trials for dichotomous variables.
    Jiang Z; Xue F; Li C; Wang L; Cai H; Zhang C; Xia J
    Contemp Clin Trials; 2010 May; 31(3):242-50. PubMed ID: 20172053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blinding in randomized clinical trials: imposed impartiality.
    Hróbjartsson A; Boutron I
    Clin Pharmacol Ther; 2011 Nov; 90(5):732-6. PubMed ID: 21993424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.